We are excited to announce the launch of the Tulobuterol Patch, a cutting-edge transdermal system designed to improve the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
This innovative patch provides a controlled and sustained release of tulobuterol, a long-acting beta-2 agonist, directly through the skin, ensuring consistent bronchodilation over an extended period. The transdermal delivery method enhances patient comfort and compliance by eliminating the need for frequent inhaler use, offering a discreet and convenient alternative for daily treatment.
Key benefits of the Tulobuterol Patch include:
- Steady medication delivery for improved symptom control
- Reduced dosing frequency, supporting better adherence
- Minimized systemic side effects thanks to targeted release
- User-friendly application suitable for a wide range of patients
We invite you to explore the detailed features, clinical data, and potential applications of this product.
For any questions, additional information, or to discuss potential collaborations, please do not hesitate to contact us at barbara@synergypharma.ch
